News
ChromaDex to Report First Quarter 2024 Financial Results on Wednesday, May 8, 2024
LOS ANGELES - ChromaDex Corp. (NASDAQ:CDXC), the global authority on nicotinamide adenine dinucleotide (NAD+) and healthy aging research, announced that it will hold a conference call on Wednesday, May 8, 2024 at 4:30 p.m. ET to discuss its financial results for the...
ChromaDex Announces Inaugural Major Grocery Debut of Tru Niagen® at Sprouts Farmers Market
Tru Niagen® expands to health-conscious Sprouts consumers in more than 400 locations across 23 states LOS ANGELES - ChromaDex Corp. (NASDAQ:CDXC), the global authority on nicotinamide adenine dinucleotide (NAD+) and healthy aging research, announces that its...
ChromaDex Announces Tru Niagen® is Now Third-Party Verified Through the Alkemist Assured™ Transparency Program
All Tru Niagen products (except Tru Niagen 1,000mg, which is NSF Certified for Sport®) are Alkemist Assured LOS ANGELES - ChromaDex Corp. (NASDAQ:CDXC), the global authority on nicotinamide adenine dinucleotide (NAD+) and healthy aging research, announces that...
ChromaDex Corporation Reports Fourth Quarter and Fiscal Year 2023 Results
Fourth quarter net sales of $21.2 million, gross margin of 61.0%, and net income of $0.1 million. Full year net sales of $83.6 million, up 16% from the prior year, gross margin of 60.8%, net loss of only $4.9 million, positive Adjusted EBITDA of $1.9 million and...
ChromaDex to Report Fourth Quarter 2023 Financial Results on Wednesday, March 6, 2024
LOS ANGELES - ChromaDex Corp. (NASDAQ:CDXC) ("the Company"), a global bioscience company dedicated to healthy aging, announced that it will hold a conference call on Wednesday, March 6, 2024 at 4:30 p.m. ET to discuss its financial results for the fourth quarter,...
ChromaDex to Participate in Renmark’s Virtual Non-Deal Roadshow on Monday, February 12, 2024
LOS ANGELES - ChromaDex Corp. (NASDAQ:CDXC), the global authority on nicotinamide adenine dinucleotide (NAD+) and healthy aging research, announced today that it will be participating in Renmark Financial Communications Inc.'s live Virtual Non-Deal Roadshow Series to...
ChromaDex to Present at the Lytham Partners 2024 Investor Select Conference
LOS ANGELES - ChromaDex Corp. (NASDAQ:CDXC), the global authority on nicotinamide adenine dinucleotide (NAD+) and healthy aging research, today announced that its Chief Executive Officer, Rob Fried, and Chief Financial Officer, Brianna Gerber, will be participating in...
ChromaDex Supports the US Military with its Industry Leading NAD+ Supplement, Tru Niagen®
Tru Niagen is now available to US troops through an exclusive Military program LOS ANGELES - ChromaDex Corp. (NASDAQ:CDXC), the global authority on nicotinamide adenine dinucleotide (NAD+) and healthy aging research, is proud to announce its inaugural initiative to...
A Milestone Phase I Randomized, Double-Blind Clinical Trial Demonstrates High-Dose Niagen®, Patented Nicotinamide Riboside (NR), Supplementation Induces a Potent NAD+ Response and Is Associated With Mild Improvement in Parkinson’s Disease (PD)
Building on a growing body of research showcasing NR as a potential therapeutic strategy for PD, this is the first clinical study to showcase the safety, tolerability, and beneficial metabolic effects of high-dose NR at 3,000 mg per day LOS ANGELES - ChromaDex Corp....
Newly Published Phase II Clinical Study Demonstrates that Supplementation with Niagen®, Patented Nicotinamide Riboside (NR), Elevates NAD+ Up to Fourfold, Improving Motor Coordination and Eye Movement in Ataxia Telangiectasia (AT) Patients
This is the longest Niagen NR clinical trial to date spanning two years and showcases that long-term Niagen NR is safe and well tolerated LOS ANGELES - ChromaDex Corp. (NASDAQ:CDXC), one of the global authorities on Nicotinamide Adenine Dinucleotide (NAD+) and healthy...